When was Unity Biotechnology founded?

Unity Biotechnology was founded in 2009 and raised its 1st funding round 7 years after it was founded.

Where is Unity Biotechnology located?

Unity Biotechnology is headquartered in San Francisco, United States.

How many employees does Unity Biotechnology have?

As of Mar 01, 2026, the latest employee count at Unity Biotechnology is 10 - 49.

Is Unity Biotechnology a funded company?

Unity Biotechnology is a funded company, having raised a total of $206M across 5 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Feb 03, 2016.

How much is Unity Biotechnology worth?

The last known valuation of Unity Biotechnology was $***** as of May 06, 2018.

When was the latest funding round of Unity Biotechnology?

Unity Biotechnology's latest funding was a $***** Conventional Debt round on Aug 04, 2020, with participation from 1 investor. Its primary sector is Neurology. In United States, the Neurology sector has seen $4.05B in funding in 2026 to date.

What is the annual revenue of Unity Biotechnology?

Annual revenue of Unity Biotechnology is less than $1M as on Dec 31, 2022

Where does Unity Biotechnology rank among its competitors?

Unity Biotechnology ranks 997th amongst 2466 active competitors, of which 840 are funded. It stands 6th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Unity Biotechnology?

Unity Biotechnology's top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Unity Biotechnology - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

Developer of therapeutics solutions for numerous diseases of aging. It offer therapeutics that prevent, halt, and reverse various diseases of aging. Its medicines target vulnerabilities unique to senescent cells to clear those cells from the human body while leaving normal cells unaffected. It has shown that removing senescent cells from animals reverses or prevents many conditions in which senescent cells are implicated, including osteoarthritis, atherosclerosis, eye diseases, and kidney diseases. The company has used a biomarker for senescence, p16(Ink4a), to design a novel transgene, INK-ATTAC, for inducible elimination of p16(Ink4a)-positive senescent cells upon administration of a drug.

Website: unitybiotechnology.com
Social

Key Metrics

Founded Year

2009

Location

San Francisco, United States

Stage

Deadpooled

Total Funding

$206M in 5 rounds

Latest Funding Round

Conventional Debt, Aug 04, 2020, $*****

Last Known Valuation

$***** as on May 06, 2018

Investors

Arch Venture Partners & 22 more

Ranked

997^th among 2466 active competitors

Annual Revenue

$0 - $1M as on Dec 31, 2022

Employee Count

10 - 49 as on Mar 01, 2026

Similar Companies

Tenpoint Therapeutics & 36 more

View Unity Biotechnology's full profile

Unity Biotechnology is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
Unity Biotechnology, Inc. CIN: 1463361 , United States, Active	Mar 29, 2009	$0 - $1M (As on Dec 31, 2022)	-	-

Unity Biotechnology has raised a total funding of $206M over 5 rounds. Its first funding round was on Feb 03, 2016. Its latest funding round was a Conventional Debt round on Aug 04, 2020 for $*****. 1 investor participated in its latest round. Unity Biotechnology has 23 institutional investors.

Here is the list of recent funding rounds of Unity Biotechnology:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Aug 04, 2020	8805033	Conventional Debt	6289412	1843966	7409828	8053058
Mar 19, 2018	7832935	Series C	8758537	2063674	3754245	6 Dimensions Capital & 10 more
Aug 17, 2017	1837213	Series B	6819630	3762201	Arch Venture Partners	Cycad Group & 10 more

Access funding benchmarks and valuations. Sign up today!

View details of Unity Biotechnology's funding rounds and investors

The founders of Unity Biotechnology are Daohong Zhou and Judith Campisi.

Here are the details of Unity Biotechnology's key team members:

Daohong Zhou: Former Co-Founder of Unity Biotechnology.
Judith Campisi: Former Co-Founder of Unity Biotechnology.

View details of Unity Biotechnology's Founder profiles and Board Members

Unity Biotechnology's employee count trend

Unity Biotechnology has 10 - 49 employees as of Mar 26. Here is Unity Biotechnology's employee count trend over the years:

Employee count trend for Unity Biotechnology

Uncover Unity Biotechnology's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Unity Biotechnology include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Here is the list of Top 10 competitors of Unity Biotechnology, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
3rd	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
4th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
5th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
6th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
7th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
8th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
9th	Elicio 2012, Cambridge (United States), Public	Developer of vaccines for treating cancer	$47.4M	Dreavent, Efung Capital & 5 others	71/100
10th	Celularity 2016, Warren (United States), Public	Developer of allogeneic cell therapies to treat multiple diseases	$290M	Celgene, Dreyfus Family Office & 8 others	71/100
997th	Unity Biotechnology 2009, San Francisco (United States), Deadpooled	Developer of therapeutics solutions for numerous diseases of aging	$206M	Fidelity Investments, Baillie Gifford & 21 others	36/100